PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 33.3% in February

PolyPid Ltd. (NASDAQ:PYPD) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,200 shares, a growth of 33.3% from the February 13th total of 6,900 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 29,000 shares, the days-to-cover ratio is presently 0.3 days.

PolyPid Stock Performance

PYPD stock traded up $0.01 during trading on Friday, reaching $2.95. 9,909 shares of the stock were exchanged, compared to its average volume of 13,253. PolyPid has a twelve month low of $2.37 and a twelve month high of $5.50. The company has a market capitalization of $30.10 million, a P/E ratio of -0.59 and a beta of 1.27. The stock has a 50 day simple moving average of $3.02 and a 200-day simple moving average of $3.23. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). As a group, sell-side analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.

Analysts Set New Price Targets

PYPD has been the topic of several analyst reports. RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of PolyPid in a research report on Tuesday, January 28th. They set a “buy” rating and a $13.00 target price on the stock. Finally, HC Wainwright lowered their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PYPD. Rosalind Advisors Inc. raised its stake in shares of PolyPid by 50.6% in the fourth quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock valued at $3,108,000 after acquiring an additional 343,353 shares during the last quarter. AIGH Capital Management LLC raised its stake in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares during the last quarter. Stonepine Capital Management LLC bought a new position in PolyPid in the 3rd quarter worth approximately $476,000. Finally, J. Goldman & Co LP bought a new position in PolyPid in the 4th quarter worth approximately $391,000. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.